Siddiqui Jawed Akhtar, Singh Aru, Chagtoo Megha, Singh Nidhi, Godbole Madan Madhav, Chakravarti Bandana
Molecular Medicine and Biotechnology Department, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow - 226014, India.
Curr Cancer Drug Targets. 2015;15(2):116-35. doi: 10.2174/1568009615666141229152256.
Breast cancer is one of the most common malignancies among women, representing nearly 30% of newly diagnosed cancers every year. Till date, various therapeutic interventions, including surgery, chemotherapy, hormonal therapy, and radiotherapy are available and are known to cause a significant decline in the overall mortality rate. However, therapeutic resistance, recurrence and lack of treatment in metastasis are the major challenges that need to be addressed. Increasing evidence suggests the presence of cancer stem cells (CSCs) in heterogeneous population of breast tumors capable of selfrenewal and differentiation and is considered to be responsible for drug resistance and recurrence. Therefore, compound that can target both differentiated cancer cells, as well as CSCs, may provide a better treatment strategy. Due to safe nature of dietary agents and health products, investigators are introducing them into clinical trials in place of chemotherapeutic agents.This current review focuses on phytochemicals, mainly flavonoids that are in use for breast cancer therapy in preclinical phase. As phytochemicals have several advantages in breast cancer and cancer stem cells, new synthetic series for breast cancer therapy from analogues of most potent natural molecule can be developed via rational drug design approach.
乳腺癌是女性中最常见的恶性肿瘤之一，每年新诊断出的癌症中近30%为乳腺癌。迄今为止，包括手术、化疗、激素治疗和放疗在内的各种治疗干预措施都已可用，并且已知这些措施能使总体死亡率显著下降。然而，治疗耐药性、复发以及转移时缺乏治疗是需要解决的主要挑战。越来越多的证据表明，在乳腺肿瘤的异质性群体中存在癌症干细胞（CSCs），它们能够自我更新和分化，并且被认为是导致耐药性和复发的原因。因此，能够同时靶向分化的癌细胞以及癌症干细胞的化合物可能会提供更好的治疗策略。由于膳食剂和保健品具有安全性，研究人员正在将它们引入临床试验以取代化疗药物。本综述聚焦于植物化学物质，主要是在临床前阶段用于乳腺癌治疗的黄酮类化合物。由于植物化学物质在乳腺癌和癌症干细胞方面具有若干优势，因此可以通过合理药物设计方法，从最有效的天然分子类似物开发出新的用于乳腺癌治疗的合成系列。
